Alan Auerbach
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
-
- Breast Cancer Treatment Studies
Papers in
- Co-authors
- Reza Shaker (1 shared paper)Benson T. Massey (1 shared paper)Edward T. Stewart (1 shared paper)RICHARD A. KOMOROWSKI (1 shared paper)Sotirios Vasilopoulos (1 shared paper)Walter J. Hogan (1 shared paper)Angel Guerrero-Zotano (1 shared paper)Carlos L. Arteaga (1 shared paper)
- Journals
- Cancer Cell (2 papers)Annals of Oncology (2 papers)Clinical Cancer Research (1 paper)The Lancet Oncology (1 paper)Gastrointestinal Endoscopy (1 paper)
- Partner nations
- United StatesAustraliaJapan
In The Last Decade
Alan Auerbach
8 papers receiving 691 citations
Alan Auerbach's Hit Papers
Peers
Comparison fields: 5 of 47
- Oncology 398
- Cancer Research 157
- Radiology, Nuclear Medicine and Imaging 117
- Pulmonary and Respiratory Medicine 161
- Rheumatology 76
Countries citing papers authored by Alan Auerbach
This map shows the geographic impact of Alan Auerbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Auerbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Auerbach more than expected).
Fields of papers citing papers by Alan Auerbach
This network shows the impact of papers produced by Alan Auerbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Auerbach. The network helps show where Alan Auerbach may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Auerbach, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 2 | 2002 | 138 | |
| 3 | 2020 | 42 | |
| 4 | 2018 | 31 | |
| 5 | 2019 | 22 | |
| 6 | 2020 | 10 | |
| 7 | 2005 | 3 | |
| 8 | 2017 | 2 |
About Alan Auerbach
Alan Auerbach is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 8 papers that have together received 709 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (5 papers), Chronic Lymphocytic Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper), Cancer Treatment and Pharmacology (1 paper), PI3K/AKT/mTOR signaling in cancer (1 paper), Cancer-related cognitive impairment studies (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Oncology (398 citations), Cancer Research (157 citations), Radiology, Nuclear Medicine and Imaging (117 citations), Pulmonary and Respiratory Medicine (161 citations) and Rheumatology (76 citations). Alan Auerbach has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Reza Shaker, Benson T. Massey, Edward T. Stewart, RICHARD A. KOMOROWSKI, Sotirios Vasilopoulos, Walter J. Hogan, Angel Guerrero-Zotano, Carlos L. Arteaga, Richard E. Cutler and Sarah Croessmann. Their work appears in journals such as Cancer Cell, Annals of Oncology, Clinical Cancer Research, The Lancet Oncology and Gastrointestinal Endoscopy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.